farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2023.169farmaec-777Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИProspects for using high-throughput sequencing methods to identify new biomarkers of response and resistance to antitumor therapyПерспективы использования методов высокопроизводительного секвенирования для поиска новых биомаркеров ответа и резистентности к противоопухолевой терапииhttps://orcid.org/0000-0003-1541-9480СорокинаМ. А.SorokinaM. А.

Сорокина Мария Андреевна – аспирант кафедры фармакологии ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России, аналитик Нейрокампуса-2030 «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России

Scopus Author ID: 57226747037

Шереметевский пр-т, д. 8, Иваново 153012

ул. Островитянова, д. 1, Москва 117997

Maria A. Sorokina – Postgraduate, Chair of Pharmacology, Ivanovo State Medical Academy; Analyst, Neurocampus-2030, Pirogov Russian National Research Medical University

Scopus Author ID: 57226747037

8 Sheremetevskiy Ave., Ivanovo 153012

1 Ostrovityanov Str., Moscow 117997

sorokina.dgoi@gmail.comhttps://orcid.org/0000-0002-1665-1188ГришинаТ. Р.GrishinaT. R.

Гришина Татьяна Романовна – д.м.н., профессор, заведующая кафедрой фармакологии

Шереметевский пр-т, д. 8, Иваново 153012

Tatiana R. Grishina – Dr. Med. Sc., Professor, Chief of Chair of Pharmacology

8 Sheremetevskiy Ave., Ivanovo 153012

Федеральное государственное бюджетное образовательное учреждение высшего образования «Ивановская государственная медицинская академия» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияIvanovo State Medical Academy; Pirogov Russian National Research Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Ивановская государственная медицинская академия» Министерства здравоохранения Российской ФедерацииРоссияIvanovo State Medical AcademyRussian Federation202327032023161126–133Copyright © Sorokina M.А., Grishina T.R., 20232023Сорокина М.А., Гришина Т.Р.Sorokina M.А., Grishina T.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/777

High-throughput next-generation sequencing (NGS) technologies such as whole exome sequencing (WES) and bulk RNA sequencing (RNA-seq) allow identification of the new biomarkers of response and resistance to antitumor therapy. Retrospective studies have shown that the state of the tumor microenvironment (TME), identified via RNA-seq, is an independent prognostic and predictive biomarker. WES and RNA-seq technologies, along with classical immunohistochemistry, provide a comprehensive analysis of the tumor and TME. Affordability of high-throughput sequencing will enable personalization of antitumor pharmacotherapy.

Технологии высокопроизводительного секвенирования (англ. next-generation sequencing, NGS), такие как полноэкзомное секвенирование (англ. whole exome sequencing, WES) и секвенирование тотальной РНК (англ. bulk RNA sequencing, RNA-seq), позволяют идентифицировать новые биомаркеры ответа и резистентности к противоопухолевой терапии. Ретроспективные исследования показали, что состояние опухолевого микроокружения (англ. tumor microenvironment, TME), установленное с помощью RNA-seq, является независимым прогностическим и предиктивным биомаркером. Технологии WES и RNA-seq наряду с классической иммуногистохимией позволяют максимально всесторонне проанализировать опухоль и TME. Все большая доступность NGS открывает новые возможности для персонализированного назначения противоопухолевой фармакотерапии.

биомаркерымикроокружение опухолигеномикатранскриптомикаиммуногистохимия.biomarkerstumor microenvironmentgenomicstranscriptomicsimmunohistochemistryРабота выполнена за счет гранта Российского научного фонда (проект № 23-21-00154 «Разработка методов прогноза свойств фармакологических препаратов по их молекулярной структуре с помощью теории топологического анализа хемографов»), ФИЦ ИУ РАН.The work was supported by a grant of the Russian Science Foundation (project No. 23-21-00154 “Development of methods for predicting the properties of pharmacological preparations based on their molecular structure using the theory of topological analysis of chemographs”), FRC IU RAS.ReferencesHan Y., Liu D., Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10 (3): 727–42.Han Y., Liu D., Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10 (3): 727–42.Naimi A., Mohammed R.N., Raji A., et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022; 20 (1): 44. https://doi.org/10.1186/s12964-022-00854-y.Naimi A., Mohammed R.N., Raji A., et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022; 20 (1): 44. https://doi.org/10.1186/s12964-022-00854-y.Bagaev A., Kotlov N., Nomie K., et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39 (6): 845–65.e7. https://doi.org/10.1016/j.ccell.2021.04.014.Bagaev A., Kotlov N., Nomie K., et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39 (6): 845–65.e7. https://doi.org/10.1016/j.ccell.2021.04.014.Jia M., Yao L., Yang Q., Chi T. Association of MSH2 expression with tumor mutational burden and the immune microenvironment in lung adenocarcinoma. Front Oncol. 2020; 10: 168. https://doi.org/10.3389/fonc.2020.00168.Jia M., Yao L., Yang Q., Chi T. Association of MSH2 expression with tumor mutational burden and the immune microenvironment in lung adenocarcinoma. Front Oncol. 2020; 10: 168. https://doi.org/10.3389/fonc.2020.00168.Del Re M., Cucchiara F., Rofi E., et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunol Immunother. 2021; 70 (6): 1667–78. https://doi.org/10.1007/s00262-020-02810-6.Del Re M., Cucchiara F., Rofi E., et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunol Immunother. 2021; 70 (6): 1667–78. https://doi.org/10.1007/s00262-020-02810-6.Ye Y., Zhang Y., Yang N., et al. Profiling of immune features to predict immunotherapy efficacy. Innovation (Camb). 2021; 3 (1): 100194. https://doi.org/10.1016/j.xinn.2021.100194.Ye Y., Zhang Y., Yang N., et al. Profiling of immune features to predict immunotherapy efficacy. Innovation (Camb). 2021; 3 (1): 100194. https://doi.org/10.1016/j.xinn.2021.100194.Casarrubios M., Provencio M., Nadal E., et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022; 10 (9): e005320. https://doi.org/10.1136/jitc-2022-005320.Casarrubios M., Provencio M., Nadal E., et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022; 10 (9): e005320. https://doi.org/10.1136/jitc-2022-005320.Feng C., Li T., Xiao J., et al. Tumor microenvironment profiling identifies prognostic signatures and suggests immunotherapeutic benefits in neuroblastoma. Front Cell Dev Biol. 2022; 10: 814836. https://doi.org/10.3389/fcell.2022.814836.Feng C., Li T., Xiao J., et al. Tumor microenvironment profiling identifies prognostic signatures and suggests immunotherapeutic benefits in neuroblastoma. Front Cell Dev Biol. 2022; 10: 814836. https://doi.org/10.3389/fcell.2022.814836.Zhu X., Tian X., Ji L., et al. A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol. 2021; 5 (1): 7. https://doi.org/10.1038/s41698-021-00142-x.Zhu X., Tian X., Ji L., et al. A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol. 2021; 5 (1): 7. https://doi.org/10.1038/s41698-021-00142-x.Sarhadi V.K., Armengol G. Molecular biomarkers in cancer biomolecules. 2022; 12 (8): 1021. https://doi.org/10.3390/biom12081021.Sarhadi V.K., Armengol G. Molecular biomarkers in cancer biomolecules. 2022; 12 (8): 1021. https://doi.org/10.3390/biom12081021.National Human Genome Research Institute. The cost of sequencing a human genome. URL: https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (дата обращения 28.01.2023).National Human Genome Research Institute. The cost of sequencing a human genome. Available at: https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (accessed 28.01.2023).Paul S.M., Mytelka D.S., Dunwiddie C.T., et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010; 9 (3): 203–14. https://doi.org/10.1038/nrd3078.Paul S.M., Mytelka D.S., Dunwiddie C.T., et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010; 9 (3): 203–14. https://doi.org/10.1038/nrd3078.Goossens N., Nakagawa S., Sun X., Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015; 4 (3): 256–69. https://doi.org/10.3978/j.issn.2218-676X.2015.06.04.Goossens N., Nakagawa S., Sun X., Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015; 4 (3): 256–69. https://doi.org/10.3978/j.issn.2218-676X.2015.06.04.Hayes D.F. Biomarker validation and testing. Mol Oncol. 2015; 9 (5): 960–6. https://doi.org/10.1016/j.molonc.2014.10.004.Hayes D.F. Biomarker validation and testing. Mol Oncol. 2015; 9 (5): 960–6. https://doi.org/10.1016/j.molonc.2014.10.004.Gion M., Trevisiol C., Fabricio A.S.C. State of the art and trends of circulating cancer biomarkers. Int J Biol Markers. 2020; 35 (1 Suppl.): 12–5. https://doi.org/10.1177/1724600819900512.Gion M., Trevisiol C., Fabricio A.S.C. State of the art and trends of circulating cancer biomarkers. Int J Biol Markers. 2020; 35 (1 Suppl.): 12–5. https://doi.org/10.1177/1724600819900512.Mocan L.P., Ilieș M., Melincovici C.S., et al. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol. 2022; 28 (15): 1508–25. https://doi.org/10.3748/wjg.v28.i15.1508.Mocan L.P., Ilieș M., Melincovici C.S., et al. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol. 2022; 28 (15): 1508–25. https://doi.org/10.3748/wjg.v28.i15.1508.Sahin U., Derhovanessian E., Miller M., et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547 (7662): 222–6. https://doi.org/10.1038/nature23003.Sahin U., Derhovanessian E., Miller M., et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547 (7662): 222–6. https://doi.org/10.1038/nature23003.Melief C.J.M. Cancer: Precision T-cell therapy targets tumours. Nature. 2017; 547 (7662): 165–7. https://doi.org/10.1038/nature23093.Melief C.J.M. Cancer: Precision T-cell therapy targets tumours. Nature. 2017; 547 (7662): 165–7. https://doi.org/10.1038/nature23093.Kharchenko P.V., Silberstein L., Scadden D.T. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014; 11 (7): 740–2. https://doi.org/10.1038/nmeth.2967.Kharchenko P.V., Silberstein L., Scadden D.T. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014; 11 (7): 740–2. https://doi.org/10.1038/nmeth.2967.Seiler Vellame D., Castanho I., Dahir A., et al. Characterizing the properties of bisulfite sequencing data: maximizing power and sensitivity to identify between-group differences in DNA methylation. BMC Genomics. 2021; 22 (1): 446. https://doi.org/10.1186/s12864-021-07721-z.Seiler Vellame D., Castanho I., Dahir A., et al. Characterizing the properties of bisulfite sequencing data: maximizing power and sensitivity to identify between-group differences in DNA methylation. BMC Genomics. 2021; 22 (1): 446. https://doi.org/10.1186/s12864-021-07721-z.Finotello F., Eduati F. Multi-omics profiling of the tumor microenvironment: paving the way to precision immuno-oncology. Front Oncol. 2018; 8: 430. https://doi.org/10.3389/fonc.2018.00430.Finotello F., Eduati F. Multi-omics profiling of the tumor microenvironment: paving the way to precision immuno-oncology. Front Oncol. 2018; 8: 430. https://doi.org/10.3389/fonc.2018.00430.Nielsen T.O., Leung S.C.Y., Rimm D.L., et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021; 113 (7): 808–19. https://doi.org/10.1093/jnci/djaa201.Nielsen T.O., Leung S.C.Y., Rimm D.L., et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021; 113 (7): 808–19. https://doi.org/10.1093/jnci/djaa201.Johnston S.R.D., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020; 38 (34): 3987–98. https://doi.org/10.1200/JCO.20.02514.Johnston S.R.D., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020; 38 (34): 3987–98. https://doi.org/10.1200/JCO.20.02514.Allison K.H., Hammond M.E.H., Dowsett M., et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020; 38 (12): 1346–66. https://doi.org/10.1200/JCO.19.02309.Allison K.H., Hammond M.E.H., Dowsett M., et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020; 38 (12): 1346–66. https://doi.org/10.1200/JCO.19.02309.Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018; 142 (11): 1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018; 142 (11): 1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.Prince E.A., Sanzari J.K., Pandya D., et al. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021; 5: 953–73. https://doi.org/10.1200/PO.20.00412.Prince E.A., Sanzari J.K., Pandya D., et al. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021; 5: 953–73. https://doi.org/10.1200/PO.20.00412.Noske A. Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC). Ann Oncol. 2019; 30 (Suppl. 5): v130–1. https://doi.org/10.1093/annonc/mdz242.Noske A. Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC). Ann Oncol. 2019; 30 (Suppl. 5): v130–1. https://doi.org/10.1093/annonc/mdz242.Laenkholm A.V., Grabau D., Møller Talman M.L. et al. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). Acta Oncol. 2018; 57 (1): 83–9. https://doi.org/10.1080/0284186X.2017.1404127.Laenkholm A.V., Grabau D., Møller Talman M.L. et al. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). Acta Oncol. 2018; 57 (1): 83–9. https://doi.org/10.1080/0284186X.2017.1404127.Barnes M., Srinivas C., Bai I., et al. Whole tumor section quantitative image analysis maximizes between-pathologists’ reproducibility for clinical immunohistochemistry-based biomarkers. Lab Invest. 2017; 97 (12): 1508–15. https://doi.org/10.1038/labinvest.2017.82.Barnes M., Srinivas C., Bai I., et al. Whole tumor section quantitative image analysis maximizes between-pathologists’ reproducibility for clinical immunohistochemistry-based biomarkers. Lab Invest. 2017; 97 (12): 1508–15. https://doi.org/10.1038/labinvest.2017.82.Pu T., Shui R., Shi J., et al. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China. BMC Cancer. 2019; 19 (1): 978. https://doi.org/10.1186/s12885-019-6210-3.Pu T., Shui R., Shi J., et al. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China. BMC Cancer. 2019; 19 (1): 978. https://doi.org/10.1186/s12885-019-6210-3.Griguolo G., Brasó-Maristany F., González-Farré B., et al. ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Cancers (Basel). 2020; 12 (7): 1902. https://doi.org/10.3390/cancers12071902.Griguolo G., Brasó-Maristany F., González-Farré B., et al. ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Cancers (Basel). 2020; 12 (7): 1902. https://doi.org/10.3390/cancers12071902.Li A., Keck J.M., Parmar S., et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol. 2021; 5 (1): 28. https://doi.org/10.1038/s41698-021-00165-4.Li A., Keck J.M., Parmar S., et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol. 2021; 5 (1): 28. https://doi.org/10.1038/s41698-021-00165-4.Akhtar M., Rashid S., Al-Bozom I.A. PD-L1 immunostaining: what pathologists need to know. Diagn Pathol. 2021; 16 (1): 94. https://doi.org/10.1186/s13000-021-01151-x.Akhtar M., Rashid S., Al-Bozom I.A. PD-L1 immunostaining: what pathologists need to know. Diagn Pathol. 2021; 16 (1): 94. https://doi.org/10.1186/s13000-021-01151-x.Tarantino P., Curigliano G., Tolaney S.M. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. Cancer Discov. 2022; 12 (9): 2026–30. https://doi.org/10.1158/2159-8290.CD-22-0703.Tarantino P., Curigliano G., Tolaney S.M. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. Cancer Discov. 2022; 12 (9): 2026–30. https://doi.org/10.1158/2159-8290.CD-22-0703.Metzger Filho O., Viale G., Trippa L., et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial. J Clin Oncol. 2019; 37 (15 Suppl.): 502. https://doi.org/10.1200/JCO.2019.37.15_suppl.502.Metzger Filho O., Viale G., Trippa L., et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial. J Clin Oncol. 2019; 37 (15 Suppl.): 502. https://doi.org/10.1200/JCO.2019.37.15_suppl.502.Lee H.J., Seo A.N., Kim E.J., et al. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 2014; 142 (6): 755–66. https://doi.org/10.1309/AJCPIRL4GUVGK3YX.Lee H.J., Seo A.N., Kim E.J., et al. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 2014; 142 (6): 755–66. https://doi.org/10.1309/AJCPIRL4GUVGK3YX.Kammerer-Jacquet S.F., Deleuze A., Saout J., et al. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int J Mol Sci. 2019; 20 (7): 1692. https://doi.org/10.3390/ijms20071692.Kammerer-Jacquet S.F., Deleuze A., Saout J., et al. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int J Mol Sci. 2019; 20 (7): 1692. https://doi.org/10.3390/ijms20071692.Zhu J., Armstrong A.J., Friedlander T.W., et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018; 6 (1): 4. https://doi.org/10.1186/s40425-018-0314-1.Zhu J., Armstrong A.J., Friedlander T.W., et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018; 6 (1): 4. https://doi.org/10.1186/s40425-018-0314-1.Brueffer C., Vallon-Christersson J., Grabau D., et al Clinical value of RNA sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden Cancerome Analysis Network-Breast Initiative. JCO Precis Oncol. 2018; 2: PO.17.00.135. https://doi.org/10.1200/PO.17.00135.Brueffer C., Vallon-Christersson J., Grabau D., et al Clinical value of RNA sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden Cancerome Analysis Network-Breast Initiative. JCO Precis Oncol. 2018; 2: PO.17.00.135. https://doi.org/10.1200/PO.17.00135.Darmon-Novello M., Adam J., Lamant L., et al. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. Histopathology. 2022; 80 (7): 1091–101. https://doi.org/10.1111/his.14651.Darmon-Novello M., Adam J., Lamant L., et al. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. Histopathology. 2022; 80 (7): 1091–101. https://doi.org/10.1111/his.14651.Duncan D.J., Scott M., Scorer P., Barker C., et al. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry. PLoS One. 2019; 14 (4): e0215393. https://doi.org/10.1371/journal.pone.0215393.Duncan D.J., Scott M., Scorer P., Barker C., et al. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry. PLoS One. 2019; 14 (4): e0215393. https://doi.org/10.1371/journal.pone.0215393.Tsimafeyeu I., Imyanitov E., Zavalishina L., et al. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020; 10 (1): 3928. https://doi.org/10.1038/s41598-020-60950-2.Tsimafeyeu I., Imyanitov E., Zavalishina L., et al. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020; 10 (1): 3928. https://doi.org/10.1038/s41598-020-60950-2.Byron S.A., Van Keuren-Jensen K.R., Engelthaler D.M., et al. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17 (5): 257–71. https://doi.org/10.1038/nrg.2016.10.Byron S.A., Van Keuren-Jensen K.R., Engelthaler D.M., et al. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17 (5): 257–71. https://doi.org/10.1038/nrg.2016.10.

The authors declare that there are no conflicts of interest present.